Contact Us
Contact Us
Contact Us

Investors

Welcome to our Investor page. Here you will find information on the latest ASX announcements, investor presentations and other shareholder information on Race Oncology.

Race Oncology

Race Oncology is a specialty pharmaceutical company focused on rediscovering and rescuing life-saving drugs that can deliver early commercial milestones. Race Oncology’s first asset is Bisantrene, a small molecule Chemotherapy drug that has been evaluated clinically for Acute Myeloid Leukaemia (AML).

ASX Announcements



DateTitle
17/05/2018Notice of General Meeting/Proxy FormDownload
15/05/2018Race appoints Oncologist to head Medical AffairsDownload
15/05/2018Race executes agreement for Bisantrene clinical trialDownload
07/05/2018Interview with Dr John CullityDownload
30/04/2018Investor UpdateDownload
27/04/2018Appendix 3Y-Bill GarnerDownload
20/04/2018Appendix 4C - quarterlyDownload
13/04/2018Appendix 3BDownload
13/04/2018Cleansing NoticeDownload
11/04/2018Race signs global distribution agreement with Durbin PLCDownload
1  2  3  4  5  6  7  

ASX: RAC

Price

Latest News

Read All Stories

Don't miss important updates

Get the latest news & announcement and stay up-to-date.

© 2018 Race Oncology. Website By Glide Agency